Andrea Camerini
Overview
Explore the profile of Andrea Camerini including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
68
Citations
846
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cortellini A, Brunetti L, Di Fazio G, Garbo E, Pinato D, Naidoo J, et al.
J Immunother Cancer
. 2025 Feb;
13(2).
PMID: 39904562
Background: Pembrolizumab monotherapy is an established front-line treatment for advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) tumor proportion score (TPS)≥50%. However, real-world data on its...
2.
Gelsomino F, Boni L, Tiseo M, Ricciardi S, Rocco D, Cortinovis D, et al.
Lung Cancer
. 2024 Dec;
199:108059.
PMID: 39700681
Background: As for squamous (Sq)-NSCLC, Checkmate-017 trial showed a significant overall survival (OS) improvement in favor of Nivolumab (Nivo) over Docetaxel in 2nd-line. We hypothesized that anticipating Nivo use, as...
3.
Camerini A, Mazzoni F, Scotti V, Tibaldi C, Sbrana A, Calabro L, et al.
J Clin Med
. 2024 Jul;
13(13).
PMID: 38999206
There are currently few data about the safety and effectiveness of chemotherapy for patients with metastatic non-small-cell lung cancer (NSCLC) who have progressed from prior immunotherapy. Data from patients with...
4.
Bisceglia I, Venturini E, Canale M, Ambrosetti M, Riccio C, Giallauria F, et al.
Eur Heart J Suppl
. 2024 May;
26(Suppl 2):ii252-ii263.
PMID: 38784673
Cardio-oncology rehabilitation (CORE) is not only an essential component of cancer rehabilitation but also a pillar of preventive cardio-oncology. Cardio-oncology rehabilitation is a comprehensive model based on a multitargeted approach...
5.
Bisceglia I, Venturini E, Canale M, Ambrosetti M, Riccio C, Giallauria F, et al.
G Ital Cardiol (Rome)
. 2024 Mar;
25(4):281-293.
PMID: 38526365
Cardio-oncology rehabilitation (CORE) is not only an essential component of cancer rehabilitation, but also a pillar of preventive cardio-oncology. CORE is a comprehensive model based on a multitargeted approach and...
6.
Leonetti A, Perrone F, Puntoni M, Maglietta G, Bordi P, Bria E, et al.
Eur J Cancer
. 2024 Mar;
202:114006.
PMID: 38489861
Purpose: The aim of this multi-center, retrospective/prospective cohort observational study was to evaluate outcomes in routine clinical practice of first-line chemo-immunotherapy with cis/carboplatin, pemetrexed and pembrolizumab in patients with advanced...
7.
Bisceglia I, Canale M, Silvestris N, Gallucci G, Camerini A, Inno A, et al.
Front Cardiovasc Med
. 2023 Nov;
10:1309921.
PMID: 37953759
[This corrects the article DOI: 10.3389/fcvm.2023.1223660.].
8.
Anpalakhan S, Signori A, Cortellini A, Verzoni E, Giusti R, Aprile G, et al.
iScience
. 2023 Oct;
26(11):107970.
PMID: 37860695
The neutrophil-to-lymphocyte ratio (NLR) and systemic immune-inflammatory index (SII) have been reported as prognosticators in non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), and melanoma. This analysis of the...
9.
Bisceglia I, Canale M, Silvestris N, Gallucci G, Camerini A, Inno A, et al.
Front Cardiovasc Med
. 2023 Oct;
10:1223660.
PMID: 37786510
In cancer, a patient is considered a survivor from the time of initial diagnosis until the end of life. With improvements in early diagnosis and treatment, the number of cancer...
10.
Canale M, Casolo G, Donati S, Bisceglia I, Puccetti C, Amoroso D, et al.
In Vivo
. 2023 Aug;
37(5):2139-2146.
PMID: 37652487
Background/aim: There is controversy around the use of high-sensitive troponin T (hs-TnT) as an early biomarker of cardiac toxicity in patients with breast cancer on trastuzumab (T). Patients And Methods:...